Why I’d dump the NMC Health share price and buy this health stock instead

The NMC share price gained nearly 10% Thursday, but I think buying now could be courting disaster.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Smith & Nephew (LSE: SN) jumped 9.6% in early trading Thursday, on the back of strong revenue growth for 2019.

The company is big in orthopaedics, making hip and knee joints, and other related technology. In a world where wealth is rising, demand for high-tech healthcare is growing too.

Revenue increased by 4.4% for the full year, and by 5.6% in the fourth quarter. That pushed group sales above $5bn for the first time in Smith & Nephew’s history.

The firm told us: “All global franchises and regions positively contributed to growth.” I think it’s telling that emerging markets saw a rise of 16.1%, and I’ll be looking there for further future gains.

Earnings per share dipped a little on a reported basis, from 76 cents a year ago to 68 cents. But on a trading basis, we saw a rise from 100.9 cents to 102.2 cents.

Dividends

Cash generated from operations increased nicely, to $1,370m (from $1,108m), and the dividend is up 4% to 37.5 cents per share.

That’s a yield of only around 1.5%, but it’s very well covered by earnings. And right now I think it’s right for Smith & Nephew to prioritise investing for growth ahead of providing big dividend income. Smith & Nephew expects to see underlying revenue growth of between 3.5% and 4.5% in 2020, and that looks in line with analyst expectations.

Smith & Nephew shares are up 38% over the past 12 months, so are they getting a bit peaky now? Forecasts suggest a 2020 price-to-earnings ratio of 24, which might look a bit high. But if growth continues apace, I think that could still turn out to be good value.

It’s a growth company on a high growth valuation, but I think it’s fully deserved.

NMC chaos

The intrigue is growing at NMC Health (LSE: NMC), whose shares blipped up nearly 10% Thursday morning.

Under pressure since Muddy Waters released a scathing attack on the company’s governance and announced a short position, founder and co-chair Bavaguthu Raghuram Shetty resigned earlier this week. It all comes amid confusion over the size of Shetty’s shareholding, with nobody really seeming to know.

There’s an ongoing legal investigation into the mystery, and the firm gave us an update on 18 February. It wasn’t nice, saying: “The board remains disappointed in the disclosures made by Dr Shetty.” It adds that the board “continues to encourage Dr Shetty and his advisers to ascertain the correct legal position in relation to his ownership of Ordinary Shares without further delay.” 

Confusion

The growing evidence seems bizarre. Shetty has apparently pledged a chunk of his shares against some bank loans. Other shareholders might own some of his reported holdings. And banks might have already sold some shares to enforce loan security. It boggles my mind.

Then on 19 February the story took a new twist. Czech investor Krupa Global Investments said it would not take a strategic stake in NMC unless Shetty is reinstated.

What should private investors do? I’m amazed that a FTSE 100 company can get into such an impenetrable mess. And if the board and chair can’t work out who owns what, how can we trust their competence in running the company’s finances?

I’ve admired NMC’s apparently successful growth in the past, but today I’d steer well clear.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »